Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors Meeting Abstract
| Authors: | Spira, A. I.; Papadopoulos, K. P.; Kim, D. W.; Parikh, A. R.; Barve, M. A.; Powderly, J. D. 2nd; Starodub, A.; Strickler, J. H.; Li, B. T.; Oberstein, P. E.; Hassan, F.; Yang, M.; McCleland, M.; Lally, S.; Lin, W.; Sohoni, S.; Hong, D. S. |
| Abstract Title: | Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors |
| Meeting Title: | 2025 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2025 Jan 23-25 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-01 |
| DOI: | 10.1200/JCO.2025.43.4_suppl.724 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| DOI/URL: | |
| Notes: | Meeting Abstract: 724 -- Source: CINAHL Plus with Full Text |
